Please login to the form below

Not currently logged in
Email:
Password:

non-small cell lung cancer

This page shows the latest non-small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

AZ’s immuno-oncology combo fails another lung cancer trial

AZ’s immuno-oncology combo fails another lung cancer trial

AZ’ s immuno-oncology combo fails another lung cancer trial. Latest failure casts doubt on company’s CTLA4 drug. ... metastatic non-small cell lung cancer (NSCLC) in the ARCTIC trial.

Latest news

  • Merck’s Keytruda meets survival challenge in NSCLC Merck’s Keytruda meets survival challenge in NSCLC

    Merck &Co’s grip on the first-line non-small cell lung cancer (NSCLC) immunotherapy market seems set to tighten, after its PD-1 inhibitor Keytruda halved the risk of death ... BMS is trying to gain ground in lung cancer via the CheckMate -227 trial

  • BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

    in several other tumour types including non-small cell lung cancer. ... Roche has also reported Sutent-topping results with it’s combination of PD-L1 inhibitor Tecentriq (atezolizumab) and well-established cancer drug Avastin (bevacizumab).

  • AZ makes case for first-line Tagrisso therapy in lung cancer AZ makes case for first-line Tagrisso therapy in lung cancer

    AZ makes case for first-line Tagrisso therapy in lung cancer. Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva. ... using Tagrisso (osimertinib) first-line in EGFR-mutated non-small cell lung cancer (NSCLC).

  • Merck’s Keytruda scores in frontline lung cancer yet again Merck’s Keytruda scores in frontline lung cancer yet again

    Merck’ s Keytruda scores in frontline lung cancer yet again. Drug improved overall survival as a monotherapy, which rival BMS’Opdivo was unable to show. ... Merck &Co is already the dominant force in first-line non-small cell lung cancer (NSCLC), and

  • Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

    Reviews start for Pfizer’ s wildcard lung cancer drug dacomitinib. Both EU and US regulatory advisors are currently assessing the drug. ... Regulatory reviews have started for Pfizer’s non-small cell lung cancer drug dacomitinib on both sides of the

More from news
Approximately 1 fully matching, plus 495 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck’s success in oncology will likely continue, driven by Keytruda’s lead in the frontline non-small cell lung cancer setting, ”says Cai Xuan, senior analyst, oncology and haematology, GlobalData. ... It will also be interesting to see how gene

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... TROP-2 is a cell surface receptor which is over-expressed by many human tumours, including cancers of the breast, colon and

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... This month's big pharma collaborations are in oncology, firstly where Novartis and BMS have entered a clinical

  • Pharma deals during August 2014 Pharma deals during August 2014

    Oncothyreon's clinical stage pipeline includes the immunotherapy candidates tecemotide (phase III - Stage III non-small cell lung cancer) and ONT-10 (phase 1 - solid tumour treatment), and the only ... 2 small molecule inhibitor in clinical development,

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    Oncology drugs under AMNOG: part two. Patient-relevant outcomes and the 'added benefit' of cancer drugs. ... Xalkori: Symptom improvement and quality of life gains add benefit. In the case of Xalkori (crizotinib), Pfizer's product targeting a subsegment

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell ... lung cancer therapy, which is

  • BIND Therapeutics appoints Andrew Hirsch as permanent CEO BIND Therapeutics appoints Andrew Hirsch as permanent CEO

    Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.

  • Axelar appoints Carl Harald Janson as CEO

    I look forward to take this potential novel cancer treatment to proof-of-concept,” said Janson. ... The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... and renal cell carcinoma (kidney cancer).

  • How pembrolizumab will change the management of advanced lung cancer

    How pembrolizumab will change the management of advanced lung cancer. The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by ... He explains that “ this data will completely change our

  • Therapy Watch expands its oncology portfolio

    Therapy Watch expands its oncology portfolio. This month  Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics